SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF
First Claim
1. A method of treating or preventing an occurrence or a recurrence of a Clostridium difficile infection, comprising administering to a human subject in need thereof an effective amount of a therapeutic composition comprising a first purified bacterial population consisting of bacteria comprising 16S rRNA sequence at least about 97% identical to a 16S rRNA sequence present in a reference Collinsella aerofaciens OTU, and a second purified bacterial population consisting of bacteria comprising 16S rRNA sequence at least about 97% identical to a 16S rRNA sequence present in a reference bacterium listed in Table 1 or Table 4, wherein at least one of the first type and the second type are cytotoxic or cytostatic to a pathogenic bacterium, wherein the therapeutic condition is administered under conditions such that the first purified bacterial population and the second purified bacterial population exert an inhibitory effect on a pathogenic bacterium present in or entering into the gastrointestinal tract of the human subject, such that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
3 Assignments
0 Petitions
Accused Products
Abstract
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
-
Citations
10 Claims
- 1. A method of treating or preventing an occurrence or a recurrence of a Clostridium difficile infection, comprising administering to a human subject in need thereof an effective amount of a therapeutic composition comprising a first purified bacterial population consisting of bacteria comprising 16S rRNA sequence at least about 97% identical to a 16S rRNA sequence present in a reference Collinsella aerofaciens OTU, and a second purified bacterial population consisting of bacteria comprising 16S rRNA sequence at least about 97% identical to a 16S rRNA sequence present in a reference bacterium listed in Table 1 or Table 4, wherein at least one of the first type and the second type are cytotoxic or cytostatic to a pathogenic bacterium, wherein the therapeutic condition is administered under conditions such that the first purified bacterial population and the second purified bacterial population exert an inhibitory effect on a pathogenic bacterium present in or entering into the gastrointestinal tract of the human subject, such that the number of Clostridium difficile bacteria present in the gastrointestinal tract is not detectably increased or is detectably decreased over a period of time.
Specification